Pfizer’s pan-KRAS inhibitor cancer drug approved for clinical trials
February 24, 2025
Source: drugdu
89
On February 17, the CDE official website announced that Pfizer's Class 1 new drug "PF-07934040 Tablets" has obtained implicit approval for clinical trials and is intended to be developed to treat advanced solid tumors carrying KRAS mutations.
PF-07934040 is a pan-KRAS inhibitor under development and is currently undergoing Phase 1 clinical trials internationally. According to Yaozhi data, this is the first time that the product has been approved for IND in China.
According to Pfizer's official website, PF-07934040 is a pan-KRAS "ON/OFF" inhibitor that has activity against wild-type (wt) KRAS and major mutant subtypes, and is inactive against NRAS or HRAS. PF-07934040 has been shown to bind to both the OFF (GDP-bound) and ON (GTP-loaded) states of KRAS wt, and has very low binding affinity to mutants, with a selectivity for binding to KRAS that is 5,000 times higher than HRAS/NRAS.
https://news.yaozh.com/archive/45010.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Career Development Guide for API and Pharmaceutical Intermediate Sales Professionals April 8, 2025
- Zhongke Chuangxing Angel+Exclusive Investment Round in ‘Saiyun Biology’ April 8, 2025
- Hengrui, Baiji, and China Biopharmaceuticals are leading the way, and China’s innovative drugs have entered the era of “billions” April 8, 2025
- Recyclable living battery achieves precise blood pressure regulation. Shenzhen team develops “coin-sized” biological battery April 8, 2025
- Yingen Biotech starts IPO today and is expected to be listed on April 15 April 8, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
